• Title/Summary/Keyword: Aceporol 330

Search Result 6, Processing Time 0.019 seconds

Toxicity of Novel Solubilizer of Paclitaxel, Aceporol 330, in Beagle Dogs

  • Kim, Yeo-Woon;Chung, Kyu-Nung;Kang, Hoon-Suk;Sheen, Yhun-Yhong
    • Biomolecules & Therapeutics
    • /
    • v.16 no.1
    • /
    • pp.61-68
    • /
    • 2008
  • In order to develop an improved paclitaxel formulation vehicle, a micelle forming solubilizer, Aceporol 330 was synthesized. It was previously reported that Aceporol 330 provided the linearity of paclitaxel plasma pharmacokinetics. In this study, the single dose toxicity test and 2-week repeated dose toxicity test of Aceporol 330 was performed in beagle dogs after intravenous administration. Single dose and 2-week repeated dose toxicity test of Aceporol 330 showed fever/generalized erythema, severe vomiting, and diarrhea in beagle dogs. However, those toxicities were less severe than those of Cremophor EL. Blood chemistry analysis of 2-week repeatedly treated beagle dogs with Aceporol 330 showed significant elevation of total cholesterol (TCHO) and triglyceride (TG) compared to that of control group. Cremophor EL also significantly increased total cholesterol (TCHO) and triglyceride (TG) as much as Aceporol 330. Results from this study indicated that Aceporol 330 was less toxic than Cremophor EL. Based on the pharmacokinetic advantages and the low toxicity of Aceporol 330 in single dose and 2-week repeated dose toxicity test, Aceporol 330 has a potential for use as a safer solubilizer for paclitaxel than Cremophor EL.

Toxicity of Aceporol 330 in Mice as Novel Solubilizer of Paclitaxel

  • Kim, Yeo-Woon;Chung, Kyu-Nung;Kang, Hoon-Suk;Sheen, Yhun-Yhong
    • Biomolecules & Therapeutics
    • /
    • v.16 no.1
    • /
    • pp.40-45
    • /
    • 2008
  • The objective of this study was to investigate the single dose and 2-week repeated dose toxicity of Aceporol 330 in ICR mice following single intravenous administration and to compare its toxicity with a commercially available solubilizer of paclitaxel, Cremophor EL. In single dose toxicity test, $LD_{50}$ of Aceporol 330 in mice was estimated to be greater than maximum applicable dose, 4 ml/kg. However, $LD_{50}$ of Cremophor EL in male mice was determined to be 4 ml/kg. Maximum tolerated dose (MTD) of males and females in Aceporol 330-treated group and MTD of females in Cremophor EL-treated group were 3 ml/kg. MTD of males in Cremophor EL-treated group was less than 3 ml/kg. Characteristic toxic symptoms, and hematological and blood chemical changes were not observed after single dose and repeated dose of Aceporol 330 or Cremophor EL. No histopathological abnormalities were found in organs of all animal groups. Based on the linear pharmacokinetic property of paclitaxel and the higher $LD_{50}$ in mice, Aceporol 330 has a potential for use as a safer solubilizer for paclitaxel than Cremophor EL.

The toxicity of Aceporol 460 as a novel high loading capacity solubilizer of paclitaxel

  • Kim, Yeo-Woon;Kim, Ja-Young;Cho, Min-Jung;Song, Hye-Weon;Lee, Min-Jae;Kim, Jong-Jae;Lee, Mi-Suk;Sheen, Yhun-Yhong
    • Proceedings of the Korea Society of Environmental Toocicology Conference
    • /
    • 2002.10a
    • /
    • pp.172-172
    • /
    • 2002
  • Previously, we reported a novel polymeric micellar solubilizer, Aceporol 330, that showed relatively low toxic effects when it was compared with that of Cremophor EL which is currently being used for paclitaxel. In this study, we have developed a new micellar solubilizer, Aceporol 460, that has 3-4 times higher loding capacity for paclitaxel than Aceporol 330. The single-dose and the repeated-dose toxicity of Aceporol 460 were evaluated in ICR mice. For single dose toxicity test, male and female mice were randomly assigned to one of five study groups to receive, and injected intravenously with dosages of 0, 3, 4mL Cremophor EL/kgbody weight, and 3, 4mL Aceporol 460/kg body weight, respectively. In both male and female mice, LD50 for Aceporol 460 can not he determined even at the maximal administrable dosage, 4mL/kg due to the high viscosity of chemical and there was no significant change in body weight, hematological and serum biochemical analysis, organ weight, and histopathological examination compared with that of Cremophor EL. For the repeated dose toxicity test, male and female mice were given the dosage of 0, 1.6mL Cremophor EL/kgbody weight/day, and 1.6mL Aceporol 460/kg body weight/day for 2 weeks. Results of repeated dose toxicity tests for 2 weeks suggested that Aceporol 460 treated group show no significant toxicological findings with body weight, hematological and serum biochemical analysis, organ weight, urinalysis, and ophthalmoscopic and histopathological examination compared with that of Cremophor EL. These results indicate that Aceporol 460 have higher paclitaxeL-loading capacity than Aceporol 330 and less toxic effects than Cremophor EL in male and female mice.

  • PDF

The toxicity of Aceporol 460 as a novel high loading capacity solubilizer of paclitaxel

  • Kim, Yeo-Woon;Kim, Ja-Young;Cho, Min-Jung;Song, Hae-Won;Lee, Min-Jae;Kim, Jong-Jae;Lee, Mi-Suk;Sheen, Yhun-Yhong
    • Proceedings of the PSK Conference
    • /
    • 2002.10a
    • /
    • pp.287.3-288
    • /
    • 2002
  • Previously. we reported a novel polymeric micellar solubilizeI'. Aceporol 330. that showed relatively low toxic effects when it was compared with that of Cremophor EL which is currently being used for paclitaxel. In this study. we have developed a new micellar solubilizeI, Aceporol 460. that has 3-4 times higher loding capacity for paclitaxel than Aceporol 330. The single-dose and the repeated-dose toxicity of Aceporol 460 were evaluated in ICR mice. (omitted)

  • PDF

THE TOXICITY OF ACEPOROL 460 AS A NOVEL HIGH LOADING CAPACITY SOLUBILIZER OF PACLITAXEL

  • Kim, Yeo-Woon;Kim, Ja-Young;Cho, Min-Jung;Song, Hye-Weon;Lee, Min-Jae;Kim, Jong-Jae;Lee, Mi-Suk;Sheen, Yhun-Yhong
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2002.11b
    • /
    • pp.160-160
    • /
    • 2002
  • Previously, we reported a novel polymeric micellar solubilizer, Aceporol 330, that showed relatively low toxic effects when it was compared with that of Cremophor EL which is currently being used for paclitaxel. In this study, we have developed a new micellar solubilizer, Aceporol 460, that has 3-4 times higher lading capacity for paclitaxel than Aceporol 330.(omitted)

  • PDF

TOXICITY TEST OF NEW SOLUBILIZER FOR PACLITAXEL IN BEAGLE DOG

  • Kim, Yeo-Woon;Min, Kyung-Nan;Syrie Pang;Song, Hye-Weon;Lee, Min-Jae;Lee, Mi-Suk;Kim, Jong-Jae;Sheen, Yhun-Yhong
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2001.11a
    • /
    • pp.89-89
    • /
    • 2001
  • Paclitaxel is currently administered i.v. as a slow infusion of a solution of the drug in an ethanol: cremophor EL: saline admixture. However, poor solubilization and toxicity are associated with this drug therapy. We have tried to develop a new surfactant for paclitaxel to improve efficacy and reduce toxicity of solubilizer. We performed the hemolysis test for chemicals which passed the paclitaxel-stabilizing test and 5 chemicals showing relatively low hemolytic effects were tested for a single dosing toxicity test. And then aceporol 330, which showed the most favorable result, was introduced to the repeated dosing toxicity tests in mouse and beagle dog. According to data based on body weight, mortality, dissection, homological test and biochemical test, Aceporol 330 exhibited much more reduced toxicity than cremophor EL.

  • PDF